What is AI-ECG studying for pulmonary hypertension?

AI-ECG is being studied as a tool to screen for elevated pulmonary arterial pressure in patients at risk of pulmonary hypertension. The study evaluates whether AI-ECG can help identify this condition early, leading to further testing and better management. It is sponsored by the National Defense Medical Center in Taiwan.

Who may be eligible for this pulmonary hypertension clinical trial?

Adults aged 50 to 85 who have had a 12-lead ECG in the past 3 months may be eligible. Both men and women can participate. People with prior diagnoses of pulmonary hypertension, certain heart muscle diseases, or who have had heart or lung transplants are not eligible. Please review eligibility criteria for more details.

Is there any cost to participate in this pulmonary hypertension clinical trial?

Study-related care, including the AI-ECG screening and any necessary tests, is provided at no cost. Personal travel or other expenses may vary and are not guaranteed to be covered. Participants should plan accordingly.

Actively Recruiting

Phase Not Applicable

Age: 50Years - 85Years

All Genders

ID07079592

Using AI-Enabled Electrocardiogram to Detect Pulmonary Hypertension in Adults Aged 50 to 85 A Randomized Controlled Trial

Led by National Defense Medical Center, Taiwan · Updated on 2026-02-24

8666

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Pulmonary hypertension is a condition that is often underdiagnosed due to its many causes. Researchers are evaluating an artificial intelligence-enabled electrocardiogram AI-ECG to screen for elevated pulmonary arterial pressure PAP in patients at high risk. This approach aims to identify pulmonary hypertension earlier, leading to further testing and potentially improving heart-related outcomes. The study is a randomized controlled trial sponsored by the National Defense Medical Center, Taiwan. Participants are divided into two groups. One group is screened with the AI-ECG system, and if they are identified as high-risk for pulmonary hypertension, they receive an echocardiogram to confirm the diagnosis and help guide treatment. The other group undergoes AI-ECG screening but continues with usual clinical care without additional echocardiography. The study uses this comparison to assess the value of AI-ECG-guided screening. During the study, participants will have ECGs and may have echocardiograms depending on their group and risk. Researchers will monitor heart measurements like pulmonary arterial pressure, left atrial size, right ventricular size, and left ventricular function within 90 days after starting the study. The main focus is on whether pulmonary arterial pressure exceeds 50 mmHg. The study lasts at least three months from randomization, with detailed heart imaging and function assessments to understand the AI-ECGs effectiveness in detecting pulmonary hypertension early.

CONDITIONS

Brief Title

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

Who Can Participate

Age: 50Years - 85Years

All Genders

Eligibility Criteria

You may qualify if you...

Men or women aged 50 to 85 years
At least one 12-lead ECG performed within the past 3 months

You will not qualify if you...

Diagnosis of pulmonary hypertension WHO Groups 1, 2, 3, 4, or 5
Diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
Prior heart, lung, or heart-lung transplant
Systolic pulmonary artery pressure greater than 50 mmHg by echocardiography before enrollment
Echocardiography performed within 3 months before the index ECG

Research Team

Chin Lin, Associate Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here